Methods
depression, GDM, anxiety
GDM
This study was nested within the TARGET Trial, a nationally representative multi-center stepped-wedge cluster randomised trial in 10 publicly funded participating hospitals in New Zealand [Women who were recruited to the TARGET Trial were invited to participate in this nested study and complete questionnaires about self-reported depression, anxiety, and health-related quality of life (HRQoL) at the time of diagnosis of GDM (baseline), 36 weeks’ gestation, and 6 months after the birth. Questionnaires were provided by designated study health professionals in each hospital and the women independently completed them and returned them during their clinic appointments or by post. The TARGET Trial was registered with the Australian New Zealand Clinical Trials Registry—ACTRN 12615000282583. Human ethics approval was granted by the Northern A Health and Disability Ethics Committee in New Zealand (14/NTA/163/AMO1). All participants provided written informed consent for participation in this nested study.